Three groups of patients with Parkinson''s disease (PD) were studied: (1) PD patients treated medically with L-Dopa and anticholinergics, (2) PD patients treated with thalamo-subthalamotomies plus medical treatment, and (3) PD patients treated with autologous adrenal medullary transplantation to right caudate nucleus plus medical treatment. Evaluations prior and 1, 6 and 12 months after treatment were accomplished with PD scales (NYPDS, UPDS, Schwab and England and Hoehn and Yahr scales). No attempt was made to compare one PD after treatment in each group. Statistical analysis was performed with the Friedman-Anova test. Group 1 did not show significant improvement at any time but deterioration at 12 months. Group 2 showed significant improvement at 1 month but at 12 months deterioration occurred mainly in the mental condition and akinesia. Group 3 did not show significant improvement at any time but at 12 months there was a tendency of improvement in self-sufficiency.

Keywords:
Parkinson, L-Dopa, Adrenal transplantation
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1995
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.